Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

Martin Faulkes retires as Executive Chairman of Volition

Key Takeaway: Martin Faulkes, the Executive Chairman of Volition, is retiring after leading the company since its inception in 2010. Under his guidance, Volition has grown significantly, establishing itself as a multi-national entity with a strong focus on innovative epigenetic technology. Faulkes will officially retire at the Annual General Meeting in July, leaving a legacy of leadership and support for the company's mission.
Price reaction · baseline $17.176 (2024-04-29 close) · hit pre-market · clean, no other VNRX news in the window
day 0 close · peak
+4.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Martin Faulkes has been instrumental in Volition's growth and strategy.
  • Volition has evolved into a multi-national company with significant achievements.
  • Faulkes' leadership has fostered innovation and a strong team culture.

Full Press Release Details

Martin Faulkes retires as Executive Chairman of Volition
Martin C Faulkes has announced he is retiring from Volition after serving as Executive Chairman since the company’s inception. He will be retiring from the board at our Annual General Meeting in July.
Martin, known as ‘Dill’, established Volition in 2010 alongside Cameron Reynolds, our Group CEO and founding scientists, Jake Micallef and Mark Eccleston. As Executive Chairman, Dill has been instrumental in developing our company strategy and leading our diverse board of directors – comprising scientists, academics, financiers, and commercial experts.
Dill started his working life as a Mathematician, undertaking his PhD at Queen Elizabeth College in London, followed by a postdoctoral post in general relativity at Queen’s University in Canada. He subsequently left academia to become a software engineer at Logica Ltd in London. He established Logica’s US subsidiary Logica Inc. in 1979 and was President and CEO for over five years, providing bespoke software to the banking and communication sectors.
In 1985, Dill was appointed Managing Director at System Programming Ltd in London, a company providing computer programming services to a wide range of industries. Dill went on to found Triad Group PLC, a computer software development company, where he was a Director from 1987 to 1998.
“Dill has been a remarkable Chairman from the very start of our journey. His vision has been at the heart of our ability to innovate. He has a steadfast belief that our groundbreaking epigenetic technology will make a real difference to society.
“Dill has steered Volition from a single, two-meter lab bench at the University of Namur in Belgium to the New York Stock Exchange, where we were listed in 2015. He has helped us navigate the inevitable ups and downs of scaling a start-up with a strong and steady hand, full support for our team, and a belief in serendipity – what is meant to be will be.
“We can’t thank Dill enough for his unwavering support for our mission, his leadership, and his wise counsel. We wish him all the very best as he embarks on his retirement and no doubt will dedicate even more time to his wide-ranging charitable activities.”
Cameron Reynolds
Group CEO and Co-Founder
Dill is the Founder and Chairman of the Dill Faulkes Educational Trust a charity committed to initiating and supporting projects that enhance the public understanding of science and mathematics, with a particular emphasis on inspiring young people into STEM subjects through enquiry-based learning.
Dill added:
“As Executive Chairman, I couldn’t be more proud of how far we have come. Volition is now a multi-national company with over 100 dedicated staff, a purpose-built R&D and manufacturing facility in Belgium and an Innovation Lab in the U.S. With a strong IP portfolio and a wide range of potential applications, Volition is on the cusp of fulfilling its mission to improve the lives of millions of people and animals worldwide through our transformational technology. I will continue to whole-heartedly support the Volition team as a shareholder.”
Fellow board member, Dr Ed Futcher, will also be retiring from our board at our Annual General Meeting in July and we are actively recruiting new members. We would like to thank Dr Futcher for his invaluable insights, support, and guidance to Volition.

Related Articles

• Press Releases VolitionRx Announces Collaboration with Sysmex
• Press Releases VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring

VolitionRx Announces Collaboration with Sysmex

VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

When is Martin Faulkes retiring from Volition?

Martin Faulkes will retire at the Annual General Meeting in July.

What role did Martin Faulkes play at Volition?

He served as Executive Chairman, guiding the company's strategy and growth.

Who will replace Martin Faulkes on the board?

Volition is actively recruiting new board members following his retirement.

What has been a significant achievement of Volition?

Volition has grown into a multi-national company with over 100 staff.

Last updated: Apr 30, 2024